Cormedix Inc. (CRMD) — 10-Q Filings
All 10-Q filings from Cormedix Inc.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (6)
-
CorMedix Soars to Profitability on Melinta Acquisition, DefenCath Sales
— Nov 12, 2025 Risk: medium
CorMedix Inc. reported a significant financial turnaround for the nine months ended September 30, 2025, achieving a net income of $149,034,859, a stark contrast -
CorMedix Remains Pre-Revenue, Focuses on DefenCath Commercialization
— Aug 7, 2025 Risk: high
CorMedix Inc. reported no revenue for the quarter ended June 30, 2025, consistent with its pre-commercialization stage. The company's net loss for the three mon -
CorMedix Inc. Files Q1 2025 10-Q Report
— May 6, 2025 Risk: low
CorMedix Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Delaware, is involved in the pharmaceuti -
CorMedix Inc. Files Q3 2024 10-Q Report
— Oct 30, 2024 Risk: low
CorMedix Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2024. The company, incorporated in Delaware, is involved in the pharmac -
CorMedix Inc. Files Q2 2024 10-Q Report
— Aug 14, 2024 Risk: low
CorMedix Inc. filed its quarterly report for the period ended June 30, 2024. The company is incorporated in Delaware and its principal executive offices are loc -
CorMedix Inc. Files Quarterly Report on Form 10-Q for Period Ended March 31, 2024
— May 9, 2024 Risk: low
CorMedix Inc. (CRMD) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. CorMedix Inc. filed a Form 10-Q for the quarterly period ended March 31, 2024.
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX